Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib plus cisplatin/gemcitabine in Japanese biliary tract cancer
jRCT2080222349Phase 1
- Sponsor
- AstraZeneca
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selumetinib in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 2 more (3 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of selumetinib plus cisplatin/gemcitabine and Determination of recommended dose of selumetinib in combination regimen.
02
Drugs
selumetinib
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on jRCT2080222349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222349.